<DOC>
	<DOCNO>NCT02411968</DOCNO>
	<brief_summary>Currently consensus post procedural follow imaging follow percutaneous cryoablation renal tumor . Interpretation conventional contrast enhance imaging ( CT MRI ) follow challenge . The objective study evaluate feasibility early evaluation therapeutic effect perform early follow image percutaneous MR-guided cryoablation pT1a renal cell carcinoma use 111In-Girentuximab-DOTA SPECT CT imaging .</brief_summary>
	<brief_title>Follow After Cryoablation Small Renal Masses .</brief_title>
	<detailed_description>With grow number small renal mass ( SRMs ) detect , grow interest minimal invasive treatment option lesion see come several advantage compare partial nephrectomy . Current guideline state patient small renal mass unfit undergo surgery , consider minimal invasive ablative treatment . Although percutaneous cryoablation show safe effective therapy SRM , consensus post procedural follow imaging aim evaluation therapeutic effect intervention early detection residual recurrent disease . Also interpretation conventional contrast enhance imaging ( CT MRI ) follow challenge due contrast enhancement necessarily indicate residual recurrent disease . The objective study evaluate feasibility early evaluation therapeutic effect perform early follow image percutaneous MR-guided cryoablation pT1a renal cell carcinoma 111In-Girentuximab-DOTA SPECT CT image . Therefore , cryoablation , target 111In-Girentuximab-DOTA SPECT CT scan perform . Additional functional 111In-Girentuximab-DOTA SPECT CT scan 4-6 week percutaneous MR-guided cryoablation small renal mass perform . The latter take place case proven target pre procedural 111In-Girentuximab-DOTA SPECT CT scan . Standard 1 3 month follow MRI treatment perform .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>&gt; 50 year age ; At least one untreated T1a tumour one kidney ( tumour â‰¤ 4 cm great dimension ) ; Signed IRBapproved informed consent form . Pregnancy breast feeding ; Known hypersensitivity HACA Girentuximab .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cryosurgery</keyword>
	<keyword>Carcinoma , renal cell</keyword>
	<keyword>Diagnostic Imaging</keyword>
	<keyword>Diagnostic technique , urological</keyword>
	<keyword>Radionuclide imaging</keyword>
	<keyword>Follow</keyword>
</DOC>